Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

NCT06070636 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06070636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06070636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Not applicable
Overall status
Recruiting
Start date
May 20, 2024
Completion date
June 30, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, immunotherapy, lenvatinib, liver diseases, sintilimab